Biochempeg Scientific Inc. developed a series of PEG compounds used for Semaglutide
Semaglutide (trade names Rybelsus, Ozempic) is a medication for the treatment of type 2 diabetes. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. It was given a brand name Ozempic. Clinical trials were started in 2015, and phase 3 was completed in 2016. Semaglutide acts like human glucagon-like peptide-1 (GLP-1) so that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen. One of its advantages over other antidiabetic drugs is that it has a long duration of action, thus, only once-a-week injection is sufficient.
Biochempeg supplies some key intermediates of Semaglutide with high quality & fast shipping. There are 4 kinds of key intermediates of Semaglutide for your research.
CatalogID: 10821 Purity: ≥95% CAS NO.: 166108-71-0
CatalogID: 10803 Purity: ≥95% CAS NO.: 134978-97-5
Price: $180/1g $600/5g
CatalogID: 10852 Purity: ≥95% CAS NO.: 108466-89-3
Price: $380/5g $600/10g
CatalogID: 12311 Purity: ≥95% CAS NO.: 134979-01-4
Company: Biochempeg Scientific Inc.
Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA